Business Description
aTyr Pharma Inc
NAICS : 325414
SIC : 2836
ISIN : US0021201035
Total Employee Number:
58Description
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.08 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | -0.18 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -13.44 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -82.4 | |||||
3-Year EBITDA Growth Rate | 19.6 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 24.2 | |||||
3-Year Book Growth Rate | -34.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.59 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.57 | |||||
9-Day RSI | 26.81 | |||||
14-Day RSI | 34.31 | |||||
3-1 Month Momentum % | 13.32 | |||||
6-1 Month Momentum % | -42.55 | |||||
12-1 Month Momentum % | -89.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.12 | |||||
Quick Ratio | 5.12 | |||||
Cash Ratio | 5.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.2 | |||||
Shareholder Yield % | -67.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -33609.47 | |||||
Net Margin % | -32003.68 | |||||
EBITDA Margin % | -32776.84 | |||||
FCF Margin % | -29004.32 | |||||
OCF Margin % | -28891.98 | |||||
ROE % | -92.33 | |||||
ROA % | -67.46 | |||||
ROIC % | -448.67 | |||||
3-Year ROIIC % | 1279.63 | |||||
ROC (Joel Greenblatt) % | -612.12 | |||||
ROCE % | -83.76 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 215.95 | |||||
PB Ratio | 0.87 | |||||
Price-to-Tangible-Book | 0.85 | |||||
EV-to-EBIT | 0.06 | |||||
EV-to-Forward-EBIT | -0.03 | |||||
EV-to-EBITDA | 0.06 | |||||
EV-to-Forward-EBITDA | -0.03 | |||||
EV-to-Revenue | -20.78 | |||||
EV-to-Forward-Revenue | 19.17 | |||||
EV-to-FCF | 0.07 | |||||
Price-to-GF-Value | 0.84 | |||||
| Price-to-Net-Current-Asset-Value | 1.14 | |||||
| Price-to-Net-Cash | 1.18 | |||||
Earnings Yield (Greenblatt) % | 1666.67 | |||||
FCF Yield % | -129.24 |
aTyr Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
aTyr Pharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-05 | In 175 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-05 | In 175 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 56 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | 0.42 (-5.80%) | ||
| Life Sciences Virtual Investor Forum | 2026-06-25 15:30 | 0.50 (+7.38%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 15:45 | 0.44 (-2.68%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 | 0.44 (+3.32%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.43 (+25.43%) | ||
| aTyr Pharma Regulatory and Clinical Update | 2026-05-11 16:30 | 0.79 (+3.13%) | ||
| General meeting for 2026 | 2026-05-11 09:00 | 0.79 (+3.13%) |
Show
Entries
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers